aTyr Pharma, Inc.(US:ATYR) Newsfile·2025-11-18 13:19Core Viewpoint - A class action lawsuit has been filed against aTyr Pharma, Inc. due to alleged securities fraud that affected shareholders between November 7, 2024, and September 12, 2025 [2][3]. Company Details - The lawsuit claims that aTyr Pharma provided misleading positive statements about the efficacy of its drug Efzofitimod while concealing material adverse facts regarding its ability to allow patients to taper off steroid usage [3][4]. - The truth about the drug's efficacy was revealed on September 15, 2025, when aTyr announced that the EFZO-FIT study did not meet its primary endpoint, specifically regarding the change from baseline in mean daily OSC dose at week 48 [4]. Stock Performance - Following the announcement of the study results, aTyr's stock price plummeted from $6.03 per share on September 12, 2025, to $1.02 per share on September 15, 2025, marking a significant decline of 83.2% in just one day [5]. Legal Action - Shareholders who suffered losses during the relevant timeframe are encouraged to seek recovery, with no cost or obligation to participate in the lawsuit [6]. Firm Background - Levi & Korsinsky LLP, the firm handling the lawsuit, has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years [7].